- Recommendation ID
- NG191/16
- Question
What is the efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific antiviral drugs or COVID-specific neutralising monoclonal antibodies in people who do not need supplemental oxygen and are within 7 days of symptom onset?
- Any explanatory notes
(if applicable) Suggested PICO (Population, Intervention, Comparator, Outcomes)
P: people with COVID-19 who do not need supplemental oxygen and are within 7 days of symptom onset
Subgroups of particular interest
• people with at least 1 risk factor for progression to severe COVID-19 disease, including (but not limited to):
• aged 60 or over
• immunosuppression
• obesity
• hypertension
• chronic lung disease
• cardiovascular disease
• cerebrovascular disease
• active cancer
• ethnic minorities
• pregnant women
• children and young people aged under 18
• people who have had different types of vaccines and/or different numbers of vaccine doses
• people who are at high risk of not mounting an antibody response when vaccinated against COVID-19#
I:
• antiviral-antiviral
• antiviral-monoclonal antibodies
C:
• standard care without the combination treatment
O:
• effectiveness outcomes
• COVID-19 related hospitalisation
• duration of COVID-19 related hospitalisation
• all-cause hospitalisation
• all-cause mortality
• need for mechanical ventilation
• need for non-invasive respiratory support
• ICU admission
• symptom alleviation
• adherence to therapy
• safety outcomes
• any adverse event
• adverse event leading to trial discontinuation
Source guidance details
- Comes from guidance
- COVID-19 rapid guideline: managing COVID-19
- Number
- NG191
- Date issued
- March 2021
Other details
Is this a recommendation for the use of a technology only in the context of research? | No |
Is it a recommendation that suggests collection of data or the establishment of a register? | No |
Last Reviewed | 23/02/2022 |